ALXO

ALX Oncology Holdings Inc. - 10-Q Summary (Q2 2026)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies. The company has no approved products and generates no product revenue. Its primary activities involve the research and development of its lead product candidate, evorpacept (a CD47 blocker), and its second candidate, ALX2004 (an EGFR-targeted antibody-drug conjugate).

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Operating Loss: Net loss decreased by approximately 31% in Q2 2026 compared to Q2 2025, and by 37% on a year-to-date basis. This improvement is primarily driven by a significant reduction in operating expenses.
• Expense Reduction: Total operating expenses declined by 32% in Q2 and 37% YTD. Research and Development (R&D) expenses dropped 27% in Q2 and 36% YTD, attributed to a strategic shift reducing the number of active clinical trials and a prior workforce reduction in early 2025.
• Lease Termination Gain: The company recorded a net gain of $0.24 million in Q2 2026 related to the termination of its Palo Alto lease, contrasting with a $3.18 million impairment charge in the same period in 2025.
• Debt Restructuring: In June 2026, the company refinanced its Oxford-SVB loan (paying off $8.2 million) and entered into a new HSBC Loan Agreement, drawing an initial $10.0 million. This resulted in a $0.90 million loss on debt extinguishment in Q2 2026.
• Capital Raise: In February 2026, the company completed a registered offering raising approximately $140.4 million in net proceeds, significantly bolstering its liquidity position.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($153.4 million) combined with the new term loan will fund operations through the first half of 2028.
• Clinical Progress:
  • Evorpacept: The ASPEN-09-Breast trial (HER2+ breast cancer) was amended to a single-arm design based on CD47 expression and dosed its first patient in January 2026. The ASPEN-CRC study was paused to streamline resources.
  • ALX2004: The Phase 1 trial for this EGFR-targeted ADC began enrolling patients in the third dose cohort in January 2026 with no dose-limiting toxicities observed in the first two cohorts.
• Risks:
  • Capital Requirements: The company expects to continue incurring significant losses and will require substantial additional capital to complete clinical development and commercialization.
  • Regulatory Uncertainty: Success depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain. The company faces risks related to the FDA's evolving guidance on clinical trial designs.
  • Debt Covenants: The new HSBC loan agreement includes covenants that restrict the company's ability to incur additional indebtedness or dispose of assets without consent.

Investor Verification Checklist

• Verify the sufficiency of the $153.4 million cash balance to fund operations through mid-2028 given the high burn rate of clinical-stage biotech.
• Confirm the specific milestones required to access the remaining $40 million available under the new HSBC Loan Agreement.
• Monitor the enrollment and data readouts for the amended ASPEN-09-Breast trial and the Phase 1 ALX2004 trial.
• Review the impact of the workforce reduction on the company's ability to execute its streamlined clinical strategy.
• Assess the dilution impact of outstanding pre-funded warrants (13.7 million shares) and options (15.9 million shares).